Industries
Biopharmaceuticals & Rare Diseases
Toutes les analyses de Biopharmaceuticals & Rare Diseases — 3 analyses.
38/100
Rocket Pharmaceuticals: Cash Buys Time, but Danon Still Has to Earn Back the Market's Trust
Rocket Pharmaceuticals (RCKT.US) is a rare-disease gene-therapy developer whose sole approved product, Kresladi, still generates no revenue, leaving cash and a $180 million voucher sale as the real near-term story. The stock trades near the value of its cash alone because the market still distrusts the pivotal Danon cardiac program after a 2025 clinical hold, even though Phase 1 data and a modified lower-dose cohort keep the thesis alive. Rating Hold: cash buys time, but Danon still has to earn back trust and Kresladi is too small to carry the valuation on its own.
45/100
BioMarin Pharmaceutical: A Rare-Disease Cash Engine in Transition
BioMarin is a profitable rare-disease biopharma whose enzyme franchise generated about 2.106 billion USD of 2025 revenue and funds the company, while VOXZOGO (926.9 million USD) drives both growth and sentiment. The Amicus acquisition diversified the portfolio into Fabry and Pompe disease and lifted 2026 revenue guidance to 3.825-3.925 billion USD, yet weekly and oral achondroplasia rivals from Ascendis and BridgeBio keep the margin of safety thin. Rating Hold: cash generation and Amicus diversification make BioMarin sturdier than sentiment implies, but VOXZOGO competition caps the upside at today's price.
55/100
38Buffett
argenx (ARGX.US / ARGX.BR) : un rapport Zen Horizon
argenx est le leader mondial des thérapies par anticorps dans les maladies auto-immunes rares et le pionnier first-in-class du champ des inhibiteurs du FcRn. Son produit phare Vyvgart (efgartigimod) est désormais approuvé dans trois indications (gMG, CIDP à l'échelle mondiale, plus le PTI au Japon), avec environ 19000 patients traités, des ventes nettes de 4.15 milliards USD sur l'exercice 2025 (+90%) et un premier résultat opérationnel positif de 1.05 milliard USD. La Vision 2030 vise 50000 patients, 10 libellés et 5 molécules en phase III. Notation Surveiller : un actif réellement solide, mais un cours de 882.41 USD qui intègre déjà une exécution sans accroc, si bien que la fenêtre d'entrée ne s'ouvre qu'en cas de repli à 720 USD ou en dessous.